Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV001808943 | SCV002059216 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency | 2021-02-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002397760 | SCV002710229 | uncertain significance | Cardiovascular phenotype | 2024-12-09 | criteria provided, single submitter | clinical testing | The p.Y580C variant (also known as c.1739A>G), located in coding exon 2 of the TNXB gene, results from an A to G substitution at nucleotide position 1739. The tyrosine at codon 580 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003136167 | SCV003827783 | uncertain significance | Vesicoureteral reflux 8 | 2019-08-16 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004779142 | SCV005388177 | uncertain significance | not provided | 2024-03-27 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |